Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseases

References

• Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol Internet]. 2013;12:609–622.
   PubMed Web of Science ®Google Scholar
• Rösler TW, Tayaranian Marvian A, Brendel M, et al. Four-repeat tauopathies [Internet]. Prog Neurobiol. Elsevier Ltd; 2019 [ cited 2020 Nov 22].
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Respondek G, Kovacs GG. New classification of tauopathies. Rev Neurol (Paris). 2018;174:664–668.
   PubMed Web of Science ®Google Scholar
• Goedert M, Eisenberg DS, Crowther RA. Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci. 2017 ;40:189–210.
   PubMed Web of Science ®Google Scholar
• De L-RS, Moretto E, Schiavo G. Knockin’ on heaven’ s door: molecular mechanisms of neuronal tau uptake. J Neurochem. 2020;1–26.
   Google Scholar
• Irwin DJ. Tauopathies as clinicopathological entities. Park Relat Disord Internet]. 2016;22:S29–S33.
   PubMed Web of Science ®Google Scholar
• Braak H, Zetterberg H, Del Tredici K, et al. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol. 2013;126:631–641.
   PubMed Web of Science ®Google Scholar
• Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol. 2017;13:457–476.
   PubMed Web of Science ®Google Scholar
• Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, et al. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry. 2015;78:672–683.
   PubMed Web of Science ®Google Scholar
• Henderson MX, Sengupta M, Trojanowski JQ, et al. Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease. Acta Neuropathol Commun. 2019;7:1–16.
   PubMed Web of Science ®Google Scholar
• Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7:257–262.
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–629.
   PubMed Web of Science ®Google Scholar
• Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535–562.
   PubMed Web of Science ®Google Scholar
• Baldacci F, Mazzucchi S, Della Vecchia A, et al. The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Rev Mol Diagn. 2020; 20: 421–441.
   PubMed Web of Science ®Google Scholar
• Baldacci F, Lista S, Vergallo A, et al. A frontline defense against neurodegenerative diseases: the development of early disease detection methods. Expert Rev Mol Diagn. 2019;19:559–563.
   PubMed Web of Science ®Google Scholar
• Xia J, Broadhurst DI, Wilson M, et al. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013;9:280–299.
   PubMed Web of Science ®Google Scholar
• Kawarabayashi T, Nakamura T, Miyashita K, et al. Novel ELISAs to measure total and phosphorylated tau in cerebrospinal fluid. Neurosci Lett. 2020;722:134826.
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;19:559–563.
   Google Scholar
• Saijo E, Metrick MA, Koga S, et al. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 2020;139:63–77.
   PubMed Web of Science ®Google Scholar
• Hampel H, O’Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14:639–652.
   Web of Science ®Google Scholar
• Del Prete E, Beatino MF, Campese N, et al. Fluid candidate biomarkers for Alzheimer’s disease: a precision medicine approach. 2020;10:221.
   Google Scholar
• Park JC, Han SH, Yi D, et al. Plasma tau/amyloid-β 1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer’s disease. Brain. 2019;142:771–786.
   PubMed Web of Science ®Google Scholar
• Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422–433.
   PubMed Web of Science ®Google Scholar
• Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer’s disease. Alzheimer’s Dement. 2019;15: 487–496.
   PubMed Web of Science ®Google Scholar
• Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol. 2019 ;76:1060–1069.
   PubMed Web of Science ®Google Scholar
• Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimer’s Dement. 2018;14:989–997.
   PubMed Web of Science ®Google Scholar
• Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med. 2020;26:379–386.
   PubMed Web of Science ®Google Scholar
• Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med. 2020 ;26:387–397.
   PubMed Web of Science ®Google Scholar
• Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. J Am Med Assoc. 2020;324:772.
   Web of Science ®Google Scholar
• Mattsson-Carlgren N, Janelidze S, Bateman R, et al. Soluble P-tau217 reflects both amyloid and tau pathology in the human brain and mediates the association of amyloid with neocortical tau. Brain. Internet]. 2020 [cited 2020 November 22];143:3234–3241.
   PubMedGoogle Scholar
• Pitt JJ. Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry. Clin Biochem Rev. 2009;30:19–34.
   PubMedGoogle Scholar
• Barthélemy NR, Horie K, Sato C, et al. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med. 2020;217.
   Web of Science ®Google Scholar
• Chieh JJ, Yang SY, Horng HE, et al. Immunomagnetic reduction assay using high-Tc superconducting-quantum-interference-device-based magnetosusceptometry. J Appl Phys. 2010 ;107:074903.
   Web of Science ®Google Scholar
• Yang SY, Chiu MJ, Chen TF, et al. Detection of plasma biomarkers using immunomagnetic reduction: a promising method for the early diagnosis of Alzheimer’s disease. Neurol Ther. 2017;6:37–56.
   PubMed Web of Science ®Google Scholar
• Lue LF, Sabbagh MN, Chiu MJ, et al. Plasma levels of Aβ42 and tau identified probable Alzheimer’s dementia: findings in two cohorts. Front Aging Neurosci. 2017;9.
   Web of Science ®Google Scholar
• Lin CH, Yang SY, Horng HE, et al. Plasma biomarkers differentiate Parkinson’s disease from atypical parkinsonism syndromes. Front Aging Neurosci. 2018 ;10.
   Web of Science ®Google Scholar
• Fan LY, Tzen KY, Chen YF, et al. The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer's Disease. Front Aging Neurosci. 2018;10:175
   Google Scholar
• Yang CC, Chiu MJ, Chen TF, et al. Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer’s disease. J Alzheimer’s Dis. 2018 ;61:1323–1332.
   PubMed Web of Science ®Google Scholar
• Manca M, Kraus A. Defining the protein seeds of neurodegeneration using real-time quaking-induced conversion assays. Biomolecules. 2020;10:1233.
   PubMed Web of Science ®Google Scholar
• Saijo E, Metrick MA, Shunsuke II, et al. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol.2020;139:63–77.
   PubMed Web of Science ®Google Scholar
• D’abramo C, D’adamio L, Giliberto L. Significance of blood and cerebrospinal fluid biomarkers for alzheimer’s disease: sensitivity, specificity and potential for clinical use. J Pers Med. 2020 ;10:1–39.
   Web of Science ®Google Scholar
• Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016 ;15:673–684.
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer’s disease. Alzheimer’s Res Ther.2013;5:9.
   Google Scholar
• Dage JL, Wennberg AMV, Airey DC, et al. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimer’s Dement. 2016 12:1226–1234.
   PubMed Web of Science ®Google Scholar
• Mattsson N, Zetterberg H, Janelidze S, et al. Plasma tau in Alzheimer disease. Neurology. 2016;87:1827–1835.
   PubMed Web of Science ®Google Scholar
• Müller S, Preische O, Göpfert JC, et al. Tau plasma levels in subjective cognitive decline: results from the DELCODE study. Sci Rep. 2017;7.
   Web of Science ®Google Scholar
• Pase MP, Beiser AS, Himali JJ, et al. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol. 2019 ;76:598–606.
   PubMed Web of Science ®Google Scholar
• Mielke MM, Hagen CE, Wennberg AMV, et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo clinic study on aging. JAMA Neurol. 2017 ;74:1073–1080.
   PubMed Web of Science ®Google Scholar
• Cavedo E, Lista S, Houot M, et al. Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology. 2020 ;94:e30–e41.
   PubMed Web of Science ®Google Scholar
• Chen J, Wojta K, Yokoyama JS, et al. Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology. 2017;88:669–676.
   Web of Science ®Google Scholar
• Quinn JP, Corbett NJ, Kellett KAB, et al. Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers.J Alzheimers Dis 2018 ;63:13-33.13–33.
   PubMed Web of Science ®Google Scholar
• Mattsson-Carlgren N, Palmqvist S, Blennow K, et al. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nat Commun. 2020;11:1–11.
   PubMed Web of Science ®Google Scholar
• Barthélemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med. 2020;26:398–407.
   PubMed Web of Science ®Google Scholar
• Suárez‐Calvet M, Karikari TK, Ashton NJ, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected. EMBO Mol Med. 2020;12:e129221.
   Web of Science ®Google Scholar
• Forrest SL, Kril JJ, Halliday GM. Cellular and regional vulnerability in frontotemporal tauopathies. Acta Neuropathol. 2019;138:705–727.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.
   PubMed Web of Science ®Google Scholar
• Arai H, Morikawa Y, Higuchi M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology.Biochem Biophys Res Commun. 1997;264:262–264.
   Google Scholar
• Schoonenboom NSM, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78:47–54.
   PubMed Web of Science ®Google Scholar
• Bech S, Hjermind LE, Salvesen L, et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Park Relat Disord. . 2012;18:69–72.
   PubMed Web of Science ®Google Scholar
• Hall S, Öhrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch Neurol. 2012;69:1445–1452.
   PubMed Web of Science ®Google Scholar
• Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86:1240–1247.
   PubMed Web of Science ®Google Scholar
• Schirinzi T, Maria G, Di G, et al. Clinical value of CSF amyloid-beta-42 and tau proteins in progressive supranuclear palsy. J Neural Transm. 2018;125:1373–1379.
   PubMed Web of Science ®Google Scholar
• Jeppsson A, Wikkelsö C, Blennow K, et al. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. Journal of Neurology, Neurosurgery, and Psychiatry. 2019;90:1117–1123.
   PubMed Web of Science ®Google Scholar
• Urakami K, Mori M, Wada K, et al. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neuroscience Letters. 1999;259:127–129.
   PubMed Web of Science ®Google Scholar
• Urakami K, Wada K, Arai H, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. Journal of the Neurological Sciences. 2001;183:95–98.
   PubMed Web of Science ®Google Scholar
• Borroni B, Gardoni F, Parnetti L, et al. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiology of Aging. 2009;30:34–40.
   PubMed Web of Science ®Google Scholar
• Aerts MB, Esselink R, Bloem BR, et al. Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Mov Disord. 2011. DOI:10.1002/mds.23341.
   Web of Science ®Google Scholar
• Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003;54:S15-S19.
   PubMed Web of Science ®Google Scholar
• Barthélemy NR, Gabelle A, Hirtz C, et al. Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer’s disease, progressive supranuclear palsy, and dementia with Lewy bodies. J Alzheimer’s Dis. 2016;51:1033–1043.
   PubMed Web of Science ®Google Scholar
• Borroni B, Malinverno M, Gardoni F, et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology. 2008;71:1796–1803.
   PubMed Web of Science ®Google Scholar
• Kuiperij HB, Verbeek MM, Borroni B. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology. 2011;76:1443.
   PubMed Web of Science ®Google Scholar
• Wagshal D, Sankaranarayanan S, Guss V, et al. Divergent CSF τ alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2015;86:244–250.
   PubMed Web of Science ®Google Scholar
• Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol.2020;19:422–433.
   PubMed Web of Science ®Google Scholar
• Constantinescu R, Axelsson M, Eriksson B. Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism. Acta Neurologica Scandinavica. 2019;140:147–156.
   PubMed Web of Science ®Google Scholar
• Rojas JC, Bang J, Lobach IV, et al. CSF neuro fi lament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 2018; 90(4): e273–e281.
   Google Scholar
• Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672–1682.
   Web of Science ®Google Scholar
• Irwin DJ, Grossman M, Weintraub D, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017;16:55.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–2477.
   PubMed Web of Science ®Google Scholar
• Murley AG, Coyle-Gilchrist I, Rouse MA, et al. Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. Brain. 2020;143:1555–1571.
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–1014.
   PubMed Web of Science ®Google Scholar
• Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. 2017;3: 17085.
   PubMed Web of Science ®Google Scholar
• van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–2098.
   PubMed Web of Science ®Google Scholar
• Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:153–174.
   PubMed Web of Science ®Google Scholar
• Chiò A, Moglia C, Canosa A, et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology. 2019;93:e984-e994.
   PubMed Web of Science ®Google Scholar
• De Silva D, Hsieh S, Caga J, et al. Motor function and behaviour across the ALS-FTD spectrum. Acta Neurol Scand. 2016;133:367–372.
   PubMed Web of Science ®Google Scholar
• Burrell JR, Kiernan MC, Vucic S, et al. Motor Neuron dysfunction in frontotemporal dementia. Brain. 2011. DOI:10.1093/brain/awr195.
   Web of Science ®Google Scholar
• Bourbouli M, Rentzos M, Bougea A, et al. Cerebrospinal fluid TAR DNA-binding protein 43 combined with tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders. Dement Geriatr Cognit Disord. 2017;44:144–152.
   PubMed Web of Science ®Google Scholar
• Foiani MS, Cicognola C, Ermann N, et al. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. J Neurol Neurosurg Psychiatry. 2019;90:740–746.
   PubMed Web of Science ®Google Scholar
• Ye LQ, Li XY, Bin ZY, et al. The discriminative capacity of CSF β-amyloid 42 and tau in neurodegenerative diseases in the Chinese population. J Neurol Sci. 2020. DOI:10.1016/j.jns.2020.116756.
   Web of Science ®Google Scholar
• Borroni B, Benussi A, Archetti S, et al. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph Lateral Scler Frontotemporal Degener. 2015. DOI:10.3109/21678421.2014.971812.
   PubMed Web of Science ®Google Scholar
• Kämälaïnen A, Herukka SK, Hartikainen P, et al. Cerebrospinal fluid biomarkers for Alzheimer’s disease in patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis with the C9ORF72 repeat expansion. Dement Geriatr Cogn Disord. 2015. DOI:10.1159/000371704.
   PubMed Web of Science ®Google Scholar
• Abu-Rumeileh S, Mometto N, Bartoletti-Stella A, et al. Cerebrospinal fluid biomarkers in patients with frontotemporal dementia spectrum: A single-center study. J Alzheimer’s Dis. 2018. DOI:10.3233/JAD-180409.
   Google Scholar
• Paterson RW, Slattery CF, Poole T, et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer’s Res Ther. 2018. DOI:10.1186/s13195-018-0361-3.
   Web of Science ®Google Scholar
• Wilke C, Deuschle C, Rattay TW, et al. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36:1072–1074.
   PubMed Web of Science ®Google Scholar
• Scarafino A, D’Errico E, Introna A, et al. Diagnostic and prognostic power of CSF tau in amyotrophic lateral sclerosis. J Neurol. 2018;265:2353–2362.
   PubMed Web of Science ®Google Scholar
• Abu-Rumeileh S, Vacchiano V, Zenesini C, et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J Neurol. 2020. DOI:10.1007/s00415-020-09761-z.
   Web of Science ®Google Scholar
• Schreiber S, Spotorno N, Schreiber F, et al. Significance of CSF NfL and tau in ALS. J Neurol. 2018. DOI:10.1007/s00415-018-9043-0.
   Web of Science ®Google Scholar
• Lanznaster D, Hergesheimer RC, Bakkouche SE, et al. Aβ1-42 and tau as potential biomarkers for diagnosis and prognosis of amyotrophic lateral sclerosis. Int J Mol Sci. 2020. DOI:10.3390/ijms21082911.
   PubMedGoogle Scholar
• Vergallo A, Carlesi C, Pagni C, et al. A single center study: aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting. Neurol Sci. 2017;38:1791–1797.
   PubMed Web of Science ®Google Scholar
• Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018. doi: 10.1212/WNL.0000000000005261.
   PubMedGoogle Scholar
• Kuiperij HB, Versleijen AAM, Beenes M, et al. Tau rather than TDP-43 proteins are potential cerebrospinal fluid biomarkers for frontotemporal lobar degeneration subtypes: a pilot study. J Alzheimer’s Dis. 2017; 55:585–595.
   Web of Science ®Google Scholar
• Spillantini MG, Crowther RA, Jakes R, et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998;95:6469–6473.
   PubMed Web of Science ®Google Scholar
• Arima K, Hirai S, Sunohara N, et al. Cellular co-localization of phosphorylated tau- and NACP/α-synuclein- epitopes in Lewy bodies in sporadic Parkinson’s disease and in dementia with Lewy bodies. Brain Res. 1999;843:53–61.
   PubMed Web of Science ®Google Scholar
• Wood SJ, Wypych J, Steavenson S, et al. α-Synuclein fibrillogenesis is nucleation-dependent: implications for the pathogenesis of Parkinson’s disease. J Biol Chem.1999;274:19509–19512.
   PubMed Web of Science ®Google Scholar
• Friedhoff P, Von Bergen M, Mandelkow EM, et al. Structure of tau protein and assembly into paired helical filaments. Biochim Biophys Acta - Mol Basis Dis. Elsevier 2000;1502: 122–132.
   PubMed Web of Science ®Google Scholar
• Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuctein. Science. 2003;300:636–640.
   PubMed Web of Science ®Google Scholar
• Souza JM, Giasson BI, Lee VMY, et al. Chaperone-like activity of synucleins. FEBS Lett. Internet]. 2000 [cited 2020 October 19];474:116–119.
   PubMed Web of Science ®Google Scholar
• Daniele S, Frosini D, Pietrobono D, et al. α-synuclein heterocomplexes with β-amyloid are increased in red blood cells of Parkinson’s disease patients and correlate with disease severity. Front Mol Neurosci. Internet]. 2018 [cited 2020 October 10];11.
   PubMed Web of Science ®Google Scholar
• Wong YC, Krainc D. α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23:1–13.
   PubMed Web of Science ®Google Scholar
• Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid β-amyloid 1–42, t-tau, p-tau 181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013 ;70:1277–1287.
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Caspell-Garcia CJ, Coffey CS, et al. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology. 2017;89:1959–1969.
   PubMed Web of Science ®Google Scholar
• Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiol Dis. 2015; 80:29–41.
   PubMed Web of Science ®Google Scholar
• Delgado-Alvarado M, Gago B, Gorostidi A, et al. Tau/α-synuclein ratio and inflammatory proteins in Parkinson’s disease: an exploratory study. Mov Disord. 2017;32:1066–1073.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson’s disease. Brain Pathol. 2010;20:633–639.;
   PubMed Web of Science ®Google Scholar
• Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy Bodies. Biol Psychiatry.2008;64:850–855.
   PubMed Web of Science ®Google Scholar
• Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid β 1–42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75:1055–1061.
   PubMed Web of Science ®Google Scholar
• Irwin DJ, Grossman M, Weintraub D, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017;16:55.
   PubMed Web of Science ®Google Scholar
• Mukaetova-Ladinska EB, Monteith R, Perry EK. Cerebrospinal fluid biomarkers for dementia with Lewy Bodies Int J Alzheimers Dis. 2010;2010:1–17.
   PubMedGoogle Scholar
• Irwin DJ, Xie SX, Coughlin D, et al. CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology. 2018;90:e1038–e1046.
   PubMed Web of Science ®Google Scholar
• Parnetti L, Lanari A, Amici S, et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer’s disease from dementia with Lewy bodies. Neurol Sci. 2001 ;22:77–78.
   PubMed Web of Science ®Google Scholar
• Schade S, Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies:72 6.
   Google Scholar
• Coughlin DG, Xie SX, Liang M, et al. Cognitive and pathological influences of tau pathology in Lewy Body disorders abstract HHS public access. Ann Neurol. 2019;85:259–271.
   PubMed Web of Science ®Google Scholar
• van der Zande JJ, Steenwijk MD, Ten Kate M, et al. Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer’s disease pathology. Neurobiol Aging. Internet]. 2018 [cited 2020 October 16];71:171–178.
   PubMed Web of Science ®Google Scholar
• Abdelnour C, Ferreira D, Oppedal K, et al. The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies. NeuroImage Clin. Internet]. 2020;27: 102333. [cited 2020 October 16.
   PubMed Web of Science ®Google Scholar
• Palma JA, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy. Auton Neurosci Basic Clin; 2018;211: 15–25.
   PubMed Web of Science ®Google Scholar
• Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372:1375–1376.
   PubMedGoogle Scholar
• Seino Y, Nakamura T, Kawarabayashi T, et al. Cerebrospinal fluid and plasma biomarkers in neurodegenerative diseases. J Alzheimer’s Dis. 2019;68:395–404.
   PubMed Web of Science ®Google Scholar
• Herbert MK, Eeftens JM, Aerts MB, et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Park Relat Disord. 2014;20:112–115.
   PubMed Web of Science ®Google Scholar
• Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69:570–580.
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. α-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230–240.
   PubMed Web of Science ®Google Scholar
• Constantinides VC, Paraskevas GP, Emmanouilidou E, et al. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. J Neurol Sci. 2017;382:91–95.
   PubMed Web of Science ®Google Scholar
• Barbour R, Kling K, Anderson JP, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 2008;5:55–59.
   PubMed Web of Science ®Google Scholar
• Wang X, Yu S, Li F, et al. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease. Neurosci Lett. 2015;599:115–119.
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014; 13:614–629.
   PubMed Web of Science ®Google Scholar
• Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci. 2001. DOI:10.1523/JNEUROSCI.21-24-j0004.2001.
   PubMed Web of Science ®Google Scholar
• Thompson PW, Ye L, Morgenstern JL, et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies. J Neurochem. 2009. DOI:10.1111/j.1471-4159.2009.05996.x.
   Web of Science ®Google Scholar
• Villemagne VL, Okamura N. In vivo tau imaging: obstacles and progress. Alzheimer’s Dement. 2014. DOI:10.1016/j.jalz.2014.04.013
   Web of Science ®Google Scholar
• Villemagne VL, Furumoto S, Fodero-Tavoletti M, et al. The challenges of tau imaging. Future Neurol. 2012;7:409–421.
   Google Scholar
• Lemoine L, Saint-Aubert L, Nennesmo I, et al. Cortical laminar tau deposits and activated astrocytes in Alzheimer’s disease visualised by 3 H-THK5117 and 3 H-deprenyl autoradiography. Sci Rep. 2017. DOI:10.1038/srep45496.
   Web of Science ®Google Scholar
• Vermeiren C, Motte P, Viot D, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018. DOI:10.1002/mds.27271.
   PubMed Web of Science ®Google Scholar
• Brosch JR, Farlow MR, Risacher SL, et al. Tau imaging in Alzheimer’s disease diagnosis and clinical trials. Neurotherapeutics. 2017;14:62–68.
   PubMed Web of Science ®Google Scholar
• Perez-Soriano A, Arena JE, Dinelle K, et al. PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins. Mov Disord. 2017. DOI:10.1002/mds.27029.
   Web of Science ®Google Scholar
• Lois C, Gonzalez I, Johnson KA, et al. PET imaging of tau protein targets: a methodology perspective. Brain Imaging Behav. 2019;13:333–344.
   PubMed Web of Science ®Google Scholar
• Barthel H. First Tau PET tracer approved: toward accurate in vivo diagnosis of Alzheimer disease. J Nucl Med. 2020;61:1409–1410.
   Web of Science ®Google Scholar
• Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960–969.
   PubMed Web of Science ®Google Scholar
• Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970. DOI:10.1016/0022-510X(70)90063-8
   PubMed Web of Science ®Google Scholar
• Xia CF, Arteaga J, Chen G, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimer’s Dement. 2013; 9:666–676.
   PubMed Web of Science ®Google Scholar
• Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimer’s Dis. 2014; doi: 10.1016/j.jalz.2012.11.008
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Pontecorvo MJ, Devous MD, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020. DOI:10.1001/jamaneurol.2020.0528.
   PubMed Web of Science ®Google Scholar
• Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. J Am Med Assoc. 2018. DOI:10.1001/jama.2018.12917.
   Web of Science ®Google Scholar
• Harada R, Okamura N, Furumoto S, et al. 18F-THK5351: A novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208–14.
   Web of Science ®Google Scholar
• Schöll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016. DOI:10.1016/j.neuron.2016.01.028.
   Web of Science ®Google Scholar
• Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016. DOI:10.1002/ana.24546.
   Web of Science ®Google Scholar
• Chiotis K, Saint-Aubert L, Savitcheva I, et al. Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging. 2016. DOI:10.1007/s00259-016-3363-z.
   PubMed Web of Science ®Google Scholar
• Cho H, Choi JY, Hwang MS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016. DOI:10.1002/ana.24711.
   Web of Science ®Google Scholar
• Cho H, Choi JY, Hwang MS, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016. DOI:10.1212/WNL.0000000000002892.
   Google Scholar
• Pontecorvo MJ, Devous MD, Navitsky M, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017. DOI:10.1093/brain/aww334.
   PubMed Web of Science ®Google Scholar
• Marshall GA, Fairbanks LA, Tekin S, et al. Early-onset Alzheimer’s disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol. 2007. DOI:10.1177/0891988706297086.
   PubMed Web of Science ®Google Scholar
• Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron. 2014;84:608–622.
   PubMed Web of Science ®Google Scholar
• Ishiki A, Okamura N, Furukawa K, et al. Longitudinal assessment of Tau pathology in patients with Alzheimer’s disease using [18F] THK-5117 positron emission tomography. PLoS One. 2015. DOI:10.1371/journal.pone.0140311.
   Google Scholar
• Jack CR, Wiste HJ, Schwarz CG, et al. Longitudinal tau PET in ageing and Alzheimer’s disease. Brain. 2018. DOI:10.1093/brain/awy059.
   Google Scholar
• Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, et al. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia. Mol Psychiatry. 2018. DOI:10.1038/mp.2017.108.
   PubMed Web of Science ®Google Scholar
• Cho H, Choi JY, Lee HS, et al. Progressive tau accumulation in Alzheimer disease: 2-year follow-up study. J Nucl Med. 2019; 60:1611–1621.
   PubMedGoogle Scholar
• Hansson O, Mormino EC. Is longitudinal tau PET ready for use in Alzheimer’s disease clinical trials? Brain. 2018;141:1241–1244.
   Web of Science ®Google Scholar
• Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016. DOI:10.1093/brain/aww027.
   Web of Science ®Google Scholar
• Dronse J, Fliessbach K, Bischof GN, et al. In vivo patterns of tau pathology, Amyloid-β burden, and Neuronal dysfunction in clinical variants of Alzheimer’s disease. J Alzheimer’s Dis. 2017;55:465–471.
   PubMed Web of Science ®Google Scholar
• Ossenkoppele R, Schonhaut DR, Baker SL, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015. DOI:10.1002/ana.24321.
   PubMed Web of Science ®Google Scholar
• Phillips JS, Das SR, McMillan CT, et al. Tau PET imaging predicts cognition in atypical variants of Alzheimer’s disease. Hum Brain Mapp. 2018. DOI:10.1002/hbm.23874.
   Web of Science ®Google Scholar
• Okamura N, Harada R, Ishiki A, et al. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging. 2018;6:305–316.
   PubMed Web of Science ®Google Scholar
• Leuzy A, Smith R, Ossenkoppele R, et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77:955–965.
   PubMed Web of Science ®Google Scholar
• Wong DF, Comley RA, Kuwabara H, et al. Characterization of 3 novel tau radiopharmaceuticals,11C-RO-963,11C-RO-643, and18F-RO-948, in healthy controls and in Alzheimer subjects. J Nucl Med. 2018. DOI:10.2967/jnumed.118.209916.
   Web of Science ®Google Scholar
• Smith R, Schöll M, Leuzy A, et al. Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. Eur J Nucl Med Mol Imaging. 2020. DOI:10.1007/s00259-019-04496-0.
   Google Scholar
• Stephens A, Seibyl J, Mueller A, et al. IC-P-220: clinical update: 18 F-PI-2620, a next generation tau pet agent evaluated in subjects with Alzheimer’s Disease And Progressive Supranuclear Palsy. Alzheimer’s Dement. 2018. DOI:10.1016/j.jalz.2018.06.2287.
   Google Scholar
• Betthauser TJ, Cody KA, Zammit MD, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18 F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019. DOI:10.2967/jnumed.118.209650.
   PubMed Web of Science ®Google Scholar
• Lohith TG, Bennacef I, Vandenberghe R, et al. Brain imaging of Alzheimer dementia patients and elderly controls with 18 F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019. DOI:10.2967/jnumed.118.208215.
   PubMed Web of Science ®Google Scholar
• Pascoal TA, Shin M, Kang MS, et al. In vivo quantification of neurofibrillary tangles with [18 F]MK-6240. Alzheimer’s Res Ther. 2018;10:74.
   Web of Science ®Google Scholar
• Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain. 2007. DOI:10.1093/brain/awm104.
   Web of Science ®Google Scholar
• Forman MS, Zhukareva V, Bergeron C, et al. Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol. 2002. DOI:10.1016/S0002-9440(10)61154-6.
   Web of Science ®Google Scholar
• Kouri N, Murray ME, Hassan A, et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain. 2011. DOI:10.1093/brain/awr234.
   PubMed Web of Science ®Google Scholar
• Ling H, Kovacs GG, Vonsattel JPG, et al. Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain. 2016. DOI:10.1093/brain/aww256.
   PubMed Web of Science ®Google Scholar
• Saeed U, Lang AE, Masellis M. Neuroimaging advances in Parkinson’s disease and atypical parkinsonian syndromes. Front Neurol. 2020;11:572976.
   PubMed Web of Science ®Google Scholar
• Ishiki A, Harada R, Okamura N, et al. Tau imaging with [18F]THK-5351 in progressive supranuclear palsy. Eur J Neurol. 2017. DOI:10.1111/ene.13164.
   PubMedGoogle Scholar
• Smith R, Schain M, Nilsson C, et al. Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord. 2017;32:108–114.
   Google Scholar
• Cho H, Choi JY, Hwang MS, et al. Subcortical 18F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord. 2017. DOI:10.1002/mds.26844.
   Web of Science ®Google Scholar
• Whitwell JL, Lowe VJ, Tosakulwong N, et al. [18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord. 2017. DOI:10.1002/mds.26834.
   Google Scholar
• Passamonti L, Rodríguez PV, Hong YT, et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain. 2017. DOI:10.1093/brain/aww340.
   PubMed Web of Science ®Google Scholar
• Hammes J, Bischof GN, Giehl K, et al. Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Mov Disord. 2017;32:170–171.
   PubMedGoogle Scholar
• Coakeley S, Cho SS, Koshimori Y, et al. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. J Cereb Blood Flow Metab. 2017. DOI:10.1177/0271678X16683695.
   PubMed Web of Science ®Google Scholar
• Kepe V, Bordelon Y, Boxer A, et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimer’s Dis. 2013. DOI:10.3233/JAD-130032.
   Web of Science ®Google Scholar
• Schonhaut DR, McMillan CT, Spina S, et al. 18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol. 2017. DOI:10.1002/ana.25060.
   PubMed Web of Science ®Google Scholar
• Brendel M, Schönecker S, Höglinger G, et al. [18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy. Front Aging Neurosci. 2018. DOI:10.3389/fnagi.2017.00440.
   Web of Science ®Google Scholar
• Hsu JL, Chen SH, Hsiao IT, et al. 18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty. Sci Rep. 2020. DOI:10.1038/s41598-020-76339-0.
   PubMed Web of Science ®Google Scholar
• Whitwell JL, Tosakulwong N, Botha H, et al. Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. Neuroimage Clin. 2020. DOI:10.1016/j.nicl.2019.102152.
   PubMed Web of Science ®Google Scholar
• Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013. DOI:10.1016/j.neuron.2013.07.037.
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Okamura N, Hasegawa T, et al. In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET. Neurology. 2016. DOI:10.1212/WNL.0000000000003375.
   Web of Science ®Google Scholar
• McMillan CT, Irwin DJ, Nasrallah I, et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:935–937.
   Web of Science ®Google Scholar
• Ali F, Whitwell JL, Martin PR, et al. [18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation. J Neurol. 2018. DOI:10.1007/s00415-018-8815-x.
   Web of Science ®Google Scholar
• Tsai RM, Bejanin A, Lesman-Segev O, et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer’s Res Ther. 2019. DOI:10.1186/s13195-019-0470-7.
   PubMed Web of Science ®Google Scholar
• Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016. DOI:10.1186/s40478-016-0315-6.
   PubMed Web of Science ®Google Scholar
• Brendel M, Barthel H, Van Eimeren T, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020. DOI:10.1001/jamaneurol.2020.2526.
   PubMed Web of Science ®Google Scholar
• Kroth H, Oden F, Molette J, et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019. doi: 10.1007/s00259-019-04397-2.
   PubMedGoogle Scholar
• Molinuevo JL, Ayton S, Batrla R, et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 2018. doi: 10.1007/s00401-018-1932-x.
   PubMed Web of Science ®Google Scholar
• Hampel H, Goetzl EJ, Kapogiannis D, et al. Biomarker-drug and liquid biopsy co-development for disease staging and targeted therapy: cornerstones for Alzheimer’s precision medicine and pharmacology. Front Pharmacol. 2019;10:1–10.
   PubMed Web of Science ®Google Scholar
• Thijssen EH, Rabinovici GD. Rapid progress toward reliable blood tests for Alzheimer disease. JAMA Neurol. 2020. doi: 10.1001/jamaneurol.2020.4200
   Web of Science ®Google Scholar
• Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat Commun. 2020 [cited 2020 December 5];11.
   PubMed Web of Science ®Google Scholar
• Janelidze S, Berron D, Smith R, et al. Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2020. doi: 10.1001/jamaneurol.2020.4201
   Web of Science ®Google Scholar
• Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. Internet]. 2003 [cited 2020 October 10];60:1696–1702.
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. α-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011 ;10: 230–240.
   PubMed Web of Science ®Google Scholar
• Hampel H, Lista S, Neri C, et al. Time for the systems-level integration of aging: resilience enhancing strategies to prevent Alzheimer’s disease. Prog Neurobiol. 2019;181:101662.
   PubMed Web of Science ®Google Scholar
• Toschi N, Lista S, Baldacci F, et al. Biomarker-guided clustering of Alzheimer’s disease clinical syndromes. Neurobiol Aging. 2019;83:42–53.
   PubMed Web of Science ®Google Scholar
• Hampel H, Caraci F, Cuello AC, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer’s disease. Front Immunol. 2020;11:11.
   PubMed Web of Science ®Google Scholar